Orteronel ((S)-Orteronel)(TAK-700) was selected as a candidate for clinical evaluation. orteronel (TAK-700) is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer.
Molecular Weight:
307.35
CAS Number:
[566939-85-3]
Formula:
C18H17N3O2
Target:
Cytochromes P450
T6051
* VAT and and shipping costs not included. Errors and price changes excepted